AMG:ETR
Amgen Inc
€389.85
arrow_upward
+0.66%(+2.55) 1D
Oct 21, 3:42:35 PM GMT+2 · EUR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMG...
Open
€384.00
High
€393.90
Low
€380.65
Mkt. cap
236.29B
Avg. vol.
580.00
Volume
396.00
52-wk high
€393.90
52-wk low
€247.65
No. of employees
32K
Open
€384.00
High
€393.90
Low
€380.65
Mkt. cap
236.29B
Avg. vol.
580.00
Volume
396.00
52-wk high
€393.90
52-wk low
€247.65
No. of employees
32K
News stories
From web sources and news partners
MarketBeat
·
4 hours ago
Amgen Inc. $AMGN Stock Holdings Raised by Robeco Institutional Asset Management B.V.
The Motley Fool
·
15 hours ago
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
GuruFocus
·
16 hours ago
Amgen Inc (AMGN) Shares Surge 3.3% -- What GF Score of 85 Tells Investors
Traders Union
·
18 hours ago
Amgen stock climbs while resistance at $447.12 approaches
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
Founded1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com
Next call in 13 days
Tue, Nov 3, 11:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $5.77
Revenue / Est. (USD)
- / 10.06B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 9.56B | 9.87B | 8.62B | 10.05B |
Cost of goods sold | 2.74B | 2.68B | 2.50B | 2.75B |
Cost of revenue | 2.74B | 2.68B | 2.50B | 2.75B |
Research and development expenses | 1.90B | 2.14B | 1.72B | 1.87B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.72B | 1.95B | 1.60B | 1.74B |
Operating expense | 3.55B | 4.18B | 3.21B | 3.73B |
Total operating expenses | 6.29B | 6.85B | 5.70B | 6.48B |
Operating income | 3.26B | 3.01B | 2.91B | 3.57B |
Other non operating income | 181.00M | 143.00M | 192.00M | 145.00M |
EBT including unusual items | 3.92B | 1.51B | 2.08B | 2.77B |
EBT excluding unusual items | 2.72B | 2.51B | 2.37B | 3.06B |
Income tax expense | 705.00M | 181.00M | 265.00M | 393.00M |
Effective tax rate | 17.98% | 11.96% | 12.72% | 14.20% |
Other operating expenses | -71.00M | 82.00M | -113.00M | 116.00M |
Net income | 3.22B | 1.33B | 1.82B | 2.38B |
Net profit margin | 33.65% | 13.51% | 21.11% | 23.62% |
Earnings per share | 5.64 | 5.29 | 5.15 | 6.29 |
Interest and investment income | - | 408.00M | - | - |
Interest expense | -685.00M | -1.06B | -657.00M | -673.00M |
Net interest expenses | -685.00M | -653.00M | -657.00M | -673.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 4.57B | 4.02B | 4.03B | 4.69B |
Gain or loss from assets sale | - | - | - | - |